{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:25:03Z","timestamp":1776716703998,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1124\/dmd.111.042820","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T03:38:19Z","timestamp":1326857899000},"page":"754-760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-Related Variants of NADPH-Cytochrome P450 Oxidoreductase Measured in a Robust In Vitro System"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniela","family":"Moutinho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Marohnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya P.","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Rueff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettie Sue","family":"Masters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Kranendonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.042820_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/FPC.0b013e32833e0cb5","article-title":"Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase","volume":"20","author":"Agrawal","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.042820_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32830054ac","article-title":"Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19","volume":"18","author":"Agrawal","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.042820_bib3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/embor.2009.82","article-title":"Structure of the open conformation of a functional chimeric NADPH cytochrome P450 reductase","volume":"10","author":"Aigrain","year":"2009","journal-title":"EMBO Rep"},{"key":"10.1124\/dmd.111.042820_bib4","first-page":"397","article-title":"Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures","volume":"11","author":"Antley","year":"1975","journal-title":"Birth Defects Orig Artic Ser"},{"key":"10.1124\/dmd.111.042820_bib5","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(04)16503-3","article-title":"Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study","volume":"363","author":"Arlt","year":"2004","journal-title":"Lancet"},{"key":"10.1124\/dmd.111.042820_bib6","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1016\/S0021-9258(19)83868-1","article-title":"Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region","volume":"257","author":"Black","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.042820_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.111.042820_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042820_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00498254.2010.523734","article-title":"CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity","volume":"41","author":"Christensen","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.042820_bib10","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1210\/me.2007-0066","article-title":"Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P","volume":"21","author":"Dhir","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1124\/dmd.111.042820_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/mutage\/gei028","article-title":"Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines","volume":"20","author":"Duarte","year":"2005","journal-title":"Mutagenesis"},{"key":"10.1124\/dmd.111.042820_bib12","doi-asserted-by":"crossref","first-page":"36628","DOI":"10.1074\/jbc.M109.054304","article-title":"Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering","volume":"284","author":"Ellis","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.042820_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/187231208785425737","article-title":"Effects of enzyme sources on midazolam 1\u2032-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase","volume":"2","author":"Emoto","year":"2008","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.111.042820_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics\u2014drug disposition, drug targets, and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.111.042820_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbrc.2010.09.035","article-title":"Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism","volume":"401","author":"Fl\u00fcck","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.111.042820_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/jc.2004-0810","article-title":"Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and\/or impaired steroidogenesis: molecular and clinical studies in 10 patients","volume":"90","author":"Fukami","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/dmd.111.042820_bib17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/bdd.374","article-title":"Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes","volume":"24","author":"Ghosal","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.111.042820_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.09.7","article-title":"Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation","volume":"10","author":"Gomes","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.111.042820_bib19","series-title":"Cytochrome P450: Structure, Mechanism and Biochemistry","first-page":"377","article-title":"Human cytochrome P450 enzymes","author":"Guengerich","year":"2005"},{"key":"10.1124\/dmd.111.042820_bib20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nprot.2009.121","article-title":"Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase","volume":"4","author":"Guengerich","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1124\/dmd.111.042820_bib21","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1074\/jbc.M807868200","article-title":"Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450","volume":"284","author":"Hamdane","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.042820_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FPC.0b013e3282f2f121","article-title":"Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism","volume":"18","author":"Hart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.042820_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1086\/429417","article-title":"Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis","volume":"76","author":"Huang","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1124\/dmd.111.042820_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1383-5718(98)00193-4","article-title":"Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: comparison of three types of expression systems","volume":"439","author":"Kranendonk","year":"1999","journal-title":"Mutat Res"},{"key":"10.1124\/dmd.111.042820_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.abb.2008.04.014","article-title":"Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase","volume":"475","author":"Kranendonk","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.111.042820_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/mutage\/13.3.263","article-title":"Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens","volume":"13","author":"Kranendonk","year":"1998","journal-title":"Mutagenesis"},{"key":"10.1124\/dmd.111.042820_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.abb.2011.06.008","article-title":"Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization","volume":"513","author":"Marohnic","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.111.042820_bib28","doi-asserted-by":"crossref","first-page":"35975","DOI":"10.1074\/jbc.M607095200","article-title":"Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase","volume":"281","author":"Marohnic","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.042820_bib29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/dmd.109.030445","article-title":"Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect","volume":"38","author":"Marohnic","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042820_bib30","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.042820_bib31","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1210\/me.2007-0245","article-title":"Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase","volume":"21","author":"Pandey","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1124\/dmd.111.042820_bib32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nbt0897-784","article-title":"Drug metabolism by Escherichia coli expressing human cytochromes P450","volume":"15","author":"Parikh","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1124\/dmd.111.042820_bib33","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1021\/bi00494a009","article-title":"NADPH-cytochrome P-450 oxidoreductase gene organization correlates with structural domains of the protein","volume":"29","author":"Porter","year":"1990","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.111.042820_bib34","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/bi00355a036","article-title":"NADPH-cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins","volume":"25","author":"Porter","year":"1986","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.111.042820_bib35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/FPC.0b013e32833f4f9b","article-title":"Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro","volume":"20","author":"Sandee","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.042820_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.042820_bib37","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0090-9556(24)13672-0","article-title":"Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates","volume":"28","author":"Stresser","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042820_bib38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0090-9556(24)13680-X","article-title":"Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches","volume":"28","author":"Venkatakrishnan","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042820_bib39","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1016\/S0021-9258(17)34250-3","article-title":"Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase","volume":"253","author":"Vermilion","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.042820_bib40","doi-asserted-by":"crossref","first-page":"8411","DOI":"10.1073\/pnas.94.16.8411","article-title":"Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes","volume":"94","author":"Wang","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.111.042820_bib41","doi-asserted-by":"crossref","first-page":"13486","DOI":"10.1073\/pnas.1106632108","article-title":"Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency","volume":"108","author":"Xia","year":"2011","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624059981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624059981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.042820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:45:13Z","timestamp":1739904313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624059981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0090955624059981"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.042820","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-Related Variants of NADPH-Cytochrome P450 Oxidoreductase Measured in a Robust In Vitro System","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.042820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}